Maria Fontanazza joins Outcomes LLC
Outcomes LLC, publisher of market-leading Med Ad News magazine and PharmaLive.com for the life sciences industry, strengthens its leadership team with the addition of Director of Content, Maria Fontanazza.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
FDA authorizes COVID-19 boosters for kids 5-11 as cases creep up
/in Antidepressants, BNT162b2 (Pfizer and BioNTech), Coronavirus Disease (COVID-19) Pandemic, Coronavirus Vaccines, COVID-19 cases, COVID-19 Deaths, COVID-19 Vaccines, Death Tolls, Fluvoxamine, Generics, Health Outcomes, Healthcare Economics Outcomes Resesarch, Pandemics, Patient Deaths, Pfizer, SARS-CoV-2 virus, TherapeuticsOn May 17, the U.S. FDA authorized a booster of Pfizer’s vaccine for kids ages 5 to 11 years. The action comes as major cities are announcing a rise in cases. Additionally, COVID-19 would have claimed over 110,000 more lives in 2021 if not for the Pfizer-BioNTech vaccine, according to a Pfizer-sponsored report on the first year of the U.S. vaccination program.
U.S. Democrats unveil bill to address baby formula shortage
/in Baby Food, Business, Democrats, FDA, Food, Infant Formulas, Nancy Pelosi, United StatesU.S. House Democrats on May 17 unveiled a bill to provide $28 million to the Food and Drug Administration to help respond to a nationwide shortage of infant formula.
Agios’ pivot to late-stage projects results in loss of 50 jobs
/in Business, Cost Cutting, Job Cuts, R&D, R&D, Reorganization, Reprioritization, RestructuringAgios Pharmaceuticals is cutting the company’s staff numbers by 50 as part of plans to lay low on exploratory research efforts to focus on the success of late-stage initiatives.
Evotec, Sernova striving for functional diabetes cure
/in Beta cells, Business, Chronic Diseases, Clinical Trials, Collaboration, Collaborations, Diabetes, Insulin, Life Sciences, Pancreatic beta cells, Partnerships, R&DTwo life sciences powerhouses are coming together to develop an off-the-shelf beta cell replacement therapy for insulin-dependent diabetes patients, which they hope will become a functional cure for both types of the disease.
Baby formula makers ramp up U.S. supplies to tackle shortage
/in Abbott, Bacterial Infections, Business, Facilities/Sites/Manufacturing, FDA, Infant Formulas, Supermarkets, TherapeuticsTop baby formula makers Reckitt Benckiser and Nestle ramped up supplies to the United States to resolve a shortage that has emptied shelves and caused panic among parents. Leading U.S. manufacturer Abbott Laboratories on May 16 announced an agreement with the Food and Drug Administration to resume production of baby formula at the company’s Michigan plant, marking a major step towards resolving the nationwide shortage.
AstraZeneca boosts COVID portfolio with RQ Bio deal
/in Acquisitions, AstraZeneca, Biotech, Business, Coronavirus Vaccines, COVID-19 Antibodies, COVID-19 shots, COVID-19 Therapeutic, COVID-19 therapeutic candidates, COVID-19 Therapeutics, COVID-19 Therapies, COVID-19 Vaccines, Evusheld (AstraZeneca), Evusheld (tixagevimab and cilgavimab; AstraZeneca), Licensing, R&D, Therapeutics, Vaxzevria (previously COVID-19 Vaccine AstraZeneca)AstraZeneca moved to bolster the company’s COVID-19 portfolio of antibodies on May 17 with a $157 million licensing deal for experimental therapies developed by newly launched biotech RQ Bio.
U.S. to allow baby formula imports amid nationwide shortage
/in Abbott, Babies, Business, Congress, Facilities, FDA, Imports, Infant Formulas, Ireland, United States, White HouseThe United States will allow baby formula imports from foreign makers that do not usually sell their products here, the Food and Drug Administration said on May 16, as it tries to ease a nationwide shortage that has left parents scrambling to feed their babies.
Coronavirus may be linked to cases of severe hepatitis in children
/in Children, COVID-19 Studies, Hospitalized COVID-19 Patients, JAMA, Kids, Liver dysfunction, Medical Journals, Oxygen Therapy, R&D, Researchers, SARS-CoV-2 virus, Severe hepatitis, The Lancet Gastroenterology & HepatologyA chain of events possibly triggered by unrecognized infection with the SARS-CoV-2 coronavirus could be causing the mysterious cases of severe hepatitis reported in hundreds of young children around the world, researchers suggest.
FDA declines to authorize common antidepressant as COVID treatment
/in Antidepressants, Brazil, Coronavirus Disease 2019 (COVID-19), Covid-19 Data, FDA, Fluvoxamine, Generics, Selective Serotonin Reuptake Inhibitors (SSRIs), TherapeuticsThe U.S. Food and Drug Administration decided not to authorize the antidepressant fluvoxamine to treat COVID-19, saying the data has not shown the drug to be an effective therapeutic for fighting the virus.